Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533517 · ClinicalTrials.gov registry record · NA
Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction
A NA study of Heart Failure and Cardiomyopathy, Dilated, sponsored by Ancora Heart.
- Active
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 18
- Study locations
NCT03533517: Active NA study of Heart Failure and Cardiomyopathy, Dilated, sponsored by Ancora Heart.
NCT03533517 is a NA study of Heart Failure and Cardiomyopathy, Dilated that is active but no longer recruiting, run by Ancora Heart. The registered enrollment target is 22 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03533517, a NA study of Heart Failure and Cardiomyopathy, Dilated, is active but no longer recruiting, sponsored by Ancora Heart.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a non-randomized, prospective, multi-center Early Feasibility Study to evaluate the AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
Primary Outcome
Device-related or procedure-related major adverse events (MAEs)
Conditions Studied
Interventions
- DEVICE AccuCinch® Ventricular Restoration
Study Locations (18)
New York
- Mt. Sinai - New York
- Columbia University Medical Center/NYPH - New York
- Montefiore Medical Center - The Bronx
Pennsylvania
- Pinnacle Health Cardiovascular Institute - Harrisburg
- Penn State Health Milton S. Hershey Medical Center - Hershey
- University of Pennsylvania - Philadelphia
Virginia
- University of Virginia School of Medicine - Charlottesville
- Carilion Roanoke Memorial - Roanoke
California
- University of California, San Francisco - San Francisco
Georgia
- Emory University Hospital Midtown - Atlanta
Kentucky
- University of Louisville - Louisville
Louisiana
- Cardiovascular Institute of the South - Houma
Minnesota
- Minneapolis Heart Foundation Institute - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2026-02-28 |
| Phase | NA |
What the registry record for NCT03533517 still lists
NCT03533517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which AccuCinch® Ventricular Restoration is the first listed.
NCT03533517 lists 18 locations in 13 states (New York, Pennsylvania, Virginia).
Frequently Asked Questions
What is clinical trial NCT03533517 about?
NCT03533517 is a clinical study titled "Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction". This is a non-randomized, prospective, multi-center Early Feasibility Study to evaluate the AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
What is the current status of trial NCT03533517?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2018-08-23. Estimated completion is 2026-02-28.
What conditions does trial NCT03533517 study?
This clinical trial studies the following conditions: Heart Failure, Cardiomyopathy, Dilated.
What interventions are being tested in trial NCT03533517?
The interventions under investigation include: AccuCinch® Ventricular Restoration (DEVICE).
Who is sponsoring clinical trial NCT03533517?
This trial is sponsored by Ancora Heart, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03533517 being conducted?
This trial has 18 study locations across California, Georgia, Kentucky, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03533517's enrollment target sits among peer trials
22 343rd of 397 higher than 55 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI